EUVIMEDEUVIMED entdecken
Open Access

A novel high dimensional approach to assess heterogeneous treatment effect in claims data

Tiansheng Wang iD, Virginia Pate iD, Richard Wyss, John B Buse iD, Michael R Kosorok iD, Til Stürmer iD

American Journal of Epidemiology · 2025

DOI: 10.1093/aje/kwaf127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Epidemiology, 2025. Verfasst von Tiansheng Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Diabetes Association, NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We tested a novel high-dimensional approach (using 1 ordinal variable per code with up to four levels: zero, occurred once, sporadically, or frequent) against the standard high-dimensional propensity score (hdPS) method (up to 3 binary variables per code) for detecting heterogeneous treatment effects (HTE). Using the iterative causal forest (iCF) subgrouping algorithm, we analyzed a new-user cohort of 8075 sodium–glucose cotransporter-2 inhibitors and 7313 glucagon-like peptide-1 receptor agonists from a 20% random Medicare sample (2015–2019) with ≥1-year parts A/B/D enrollment and without severe renal disease. We extracted the top 200 prevalent codes across diagnoses, procedures, and prescriptions during the 1-year baseline. Subgroup-specific conditional average treatment effects (CATEs) were assessed for 2-year risk differences (aRD) in hospitalized heart failure using inverse-probability treatment weighting. The overall population exhibited an aRD of −0.4% (95% CI, −1.1% to 0.2%). Our high-dimensional setting identified patients with ≥2 loop diuretic prescriptions (aRD, −2.6%, 95% CI, −5.0% to -0.2%) as the subgroup with the largest CATE. In contrast, the high-dimensional setting from hdPS identified patients with chronic kidney disease (aRD, −1.7%, 95% CI, −3.6% to 0.2%). Across various sensitivity analyses, our high-dimensional approach more accurately identified expected subgroups with HTE that aligns with prior clinical evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHeart FailureHumansUnited StatesAgedPropensity ScoreFemaleMedicareMaleInsurance Claim ReviewAlgorithmsAged, 80 and overTreatment Effect Heterogeneity

Stichwörter der Autor:innen

causal machine learningclaims dataheterogeneous treatment effecthigh-dimensionaliterative causal forestpharmacoepidemiologyprecision medicinesubgroup identification

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.
  • Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
  • Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

ORCID-Profile: Tiansheng Wang, Virginia Pate, John B Buse, Michael R Kosorok, Til Stürmer

Förderung

  • American Diabetes Association
  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Wang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2025). A novel high dimensional approach to assess heterogeneous treatment effect in claims data. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwaf127

Vancouver

Wang T, Pate V, Wyss R, Buse JB, Kosorok MR, Stürmer T. A novel high dimensional approach to assess heterogeneous treatment effect in claims data. American Journal of Epidemiology. 2025. doi:10.1093/aje/kwaf127

BibTeX
@article{Wang2025,
  author = {Wang, Tiansheng and Pate, Virginia and Wyss, Richard and Buse, John B and Kosorok, Michael R and Stürmer, Til},
  title = {A novel high dimensional approach to assess heterogeneous treatment effect in claims data},
  journal = {American Journal of Epidemiology},
  year = {2025},
  doi = {10.1093/aje/kwaf127}
}
Kostenlos starten →